scholarly article | Q13442814 |
P356 | DOI | 10.1086/505210 |
P698 | PubMed publication ID | 16779754 |
P50 | author | Ammarin Thakkinstian | Q47152142 |
Kiat Ruxrungtham | Q66733145 | ||
P2093 | author name string | Somnuek Sungkanuparph | |
Weerawat Manosuthi | |||
Sirirat Likanonsakul | |||
Wisit Prasithsirikul | |||
Sasivimol Rattanasiri | |||
Achara Chaovavanich | |||
P433 | issue | 2 | |
P921 | main subject | nevirapine | Q263713 |
rifampicin | Q422652 | ||
P304 | page(s) | 253-255 | |
P577 | publication date | 2006-06-12 | |
P1433 | published in | Clinical Infectious Diseases | Q5133764 |
P1476 | title | Plasma nevirapine levels and 24-week efficacy in HIV-infected patients receiving nevirapine-based highly active antiretroviral therapy with or without rifampicin | |
P478 | volume | 43 |
Q55417509 | Clinical, Immunological and Virological Responses of Zidovudine-Lamivudine-Nevirapine versus Zidovudine-Lamivudine-Efavirenz Antiretroviral Treatment (ART) Among HIV-1 Infected Children: Asella Teaching and Referral Hospital, South-East Ethiopia. |
Q26991633 | Diagnosis & treatment of tuberculosis in HIV co-infected patients |
Q24609011 | Dose adjustment of the non-nucleoside reverse transcriptase inhibitors during concurrent rifampicin-containing tuberculosis therapy: one size does not fit all |
Q33375532 | Durability of stavudine, lamivudine and nevirapine among advanced HIV-1 infected patients with/without prior co-administration of rifampicin: a 144-week prospective study |
Q36576089 | Early virological response of zidovudine/lamivudine/abacavir for patients co-infected with HIV and tuberculosis in Uganda |
Q34571594 | Effectiveness of efavirenz-based regimens in young HIV-infected children treated for tuberculosis: a treatment option for resource-limited settings |
Q35530299 | Guidelines for antiretroviral therapy in HIV-1 infected adults and adolescents 2014, Thailand |
Q37390235 | HIV and tuberculosis in India |
Q34710641 | Nevirapine or efavirenz for tuberculosis and HIV coinfected patients: exposure and virological failure relationship |
Q59650851 | Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a randomised non-inferiority trial |
Q47102399 | Nevirapine- versus Efavirenz-based antiretroviral therapy regimens in antiretroviral-naive patients with HIV and Tuberculosis infections in India: a multi-centre study |
Q52330065 | Pharmacokinetics of efavirenz in patients on antituberculosis treatment in high HIV and tuberculosis burden countries: a systematic review. |
Q33364134 | Population pharmacokinetics of nevirapine in combination with rifampicin-based short course chemotherapy in HIV- and tuberculosis-infected South African patients. |
Q35689833 | Safety and efficacy of a generic fixed-dose combination of stavudine, lamivudine and nevirapine antiretroviral therapy between HIV-infected patients with baseline CD4 <50 versus CD4 > or = 50 cells/mm3. |
Q37227388 | Safety and efficacy of nevirapine- and efavirenz-based antiretroviral treatment in adults treated for TB-HIV co-infection in Botswana |
Q35571505 | The antiretroviral efficacy of highly active antiretroviral therapy and plasma nevirapine concentrations in HIV-TB co-infected Indian patients receiving rifampicin based antituberculosis treatment |
Q30658709 | The effect of tuberculosis treatment on virologic and CD4+ cell count response to combination antiretroviral therapy: a systematic review |
Q36688887 | Tuberculosis and HIV co-infection: a practical therapeutic approach |
Search more.